In this episode, Marian M.P. Temelkov, Global CEO at Dynamis Group, welcomes to the podcast Keith Williams - Co-founder and Managing Director at Phenotypeca.
Tune in and discover:
✔️ What is bioscience and what does it have in store for humanity,
✔️ How to create a caring environment for teams to thrive,
✔️ Applying care when facing adversity,
✔️ The role of effective communication when leading diverse teams,
✔️ About the ability to recharge, and more!
Keith Williams is Co-founder and Managing Director of Phenotypeca, the ‘go-to’ platform for the development of baker’s yeast strains that is making life-saving medicines more affordable and accessible for all that need them. He is an entrepreneur, investor and director with over thirty years’ global experience in the IT and Healthcare sectors and a strong interest in the intersection of the two disciplines.
Keith has used this expertise to spearhead multiple industry-leading biotechnology projects, most recently assembling a consortium of world leaders in robotics, automation, artificial intelligence, and machine learning to collectively develop a revolutionary Lab 4.0 approach. Keith has an MSc in Biochemical Engineering and a BSc in Biological Sciences from the University of Birmingham, and is a self-confessed cricket nut.
About Phenotypeca:
Phenotypeca is becoming the ‘go-to’ platform for the development of baker’s yeast strains for industrial-scale manufacture of vaccines, therapeutic and other recombinant proteins. These markets had over $200billion in revenue globally in 2020 and Phenotypeca offers an animal free, sustainable option for both these specific markets and other industrial applications.
Phenotypeca has generated the World’s largest collection of diverse baker’s yeast strains engineered for industrial recombinant protein production and is developing the ground-breaking Lab 4.0 approach alongside a consortium of World leaders in machine learning, robotics and artificial intelligence. Phenotypeca is currently fundraising and was recently awarded a grant by the Bill and Melinda Gates Foundation for a project in the vaccine development space.
Tune in!
